enGene (ENGN) Projected to Announce Quarterly Earnings on Monday

Key Points

• enGene is expected to report Q3 2026 earnings before the market opens on September 14, with analysts forecasting a loss of $0.47 per share. The earnings call is scheduled for September 16 at 9:30 a.m. ET.
• The company reported a Q2 loss of $0.43 per share, beating the consensus estimate of a $0.48 loss. Analysts expect enGene to post losses of approximately $2 per share in both the current and next fiscal years.
• ENGN shares opened at $1.82 and have fallen sharply from their 52-week high of $12.25; the stock carries a consensus “Hold” rating, while recent analysts have cut price targets and some downgraded their ratings.

enGene (NASDAQ:ENGN - Get Free Report) is expected to issue its Q3 2026 results before the market opens on Monday, September 14th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors can check the company's upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, September 16, 2026 at 9:30 AM ET.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. During the same period in the previous year, the business earned $0.51 earnings per share. On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Price Performance

NASDAQ ENGN opened at $1.82 on Monday. The company has a market capitalization of $121.92 million, a PE ratio of -0.84 and a beta of -0.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The business's fifty day moving average is $1.82 and its 200 day moving average is $4.17. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25.

Institutional Trading of enGene

Several institutional investors have recently made changes to their positions in ENGN. Cresset Asset Management LLC purchased a new position in enGene in the 2nd quarter worth approximately $36,000. Paloma Partners Management Co bought a new position in enGene in the 2nd quarter worth approximately $38,000. Raymond James Financial Inc. grew its holdings in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after buying an additional 7,932 shares in the last quarter. Jump Financial LLC purchased a new stake in enGene during the 4th quarter valued at approximately $121,000. Finally, Millennium Management LLC raised its position in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company's stock valued at $140,000 after buying an additional 7,472 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company's stock.

Analyst Upgrades and Downgrades

ENGN has been the topic of several recent research reports. UBS Group decreased their price objective on enGene from $9.00 to $2.00 and set a "neutral" rating on the stock in a research note on Thursday, May 14th. HC Wainwright reduced their target price on shares of enGene from $6.00 to $4.00 and set a "buy" rating for the company in a report on Tuesday, June 16th. Wall Street Zen upgraded shares of enGene from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of enGene in a report on Wednesday, August 12th. Finally, Morgan Stanley downgraded shares of enGene from an "equal weight" rating to an "underweight" rating and set a $3.00 price target on the stock. in a report on Thursday, June 18th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $11.05.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source